Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Purinostat mesylate in relapsed/refractory B-cell hematologic malignancies
NCT05526313Phase 1Completed
- Sponsor
- Zenitar
- Start
- Aug 2020
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of purinostat in diffuse large B-cell lymphoma (DLBCL), B cell lymphoma, multiple myeloma (MM) and 3 more (7 arms), sponsored by Zenitar. Primary endpoints: Maximum Plasma Concentration at 72 hours, Time to Maximum Plasma Concentration at 72 hours and 11 more. Started Aug 2020; status: completed.
02
Drugs
purinostat
03
Conditions
diffuse large B-cell lymphoma (DLBCL)B cell lymphomamultiple myeloma (MM)B cell acute lymphoblastic leukemia (B-ALL)T-cell lymphoma
Beyond the preview
Go deeper on NCT05526313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05526313.